Association between use of ß2-adrenergic receptor agonists and incidence of Parkinson’s disease: Retrospective cohort analysis

Keyphrases

• Parkinson's Disease 100%
• Retrospective Cohort Analysis 100%
• Adrenergic Receptor Agonists 100%
• Asthma 66%
• Disease Onset 66%
• Odds Ratio 33%
• Protective Effect 33%
• Decision Maker 33%
• Clinical Trials 33%
• United States 33%
• Neurodegenerative Diseases 33%
• Inclusion Criteria 33%
• Logistic Regression Analysis 33%
• Comorbidity 33%
• Conflicting Results 33%
• Drug Use 33%
• Smokers 33%
• Medicare 33%
• Over 65 33%
• Smoking History 33%
• Risk Reduction 33%
• Prescription Drugs 33%
• Decreased Risk 33%
• Medicare Beneficiaries 33%
• Asthmatic 33%
• Fee-for-service 33%
• Clinical Decisions 33%
• Cox Analysis 33%
• Repurposing 33%
• Co-agonist 33%
• Drug Claims 33%
• Respiratory Exacerbation 33%
• Chronic Lung Disease 33%
• Medication Initiation 33%
• Reverse Causality 33%
• Bronchiectasis 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Parkinson's Disease 100%
• Adrenergic Receptor Stimulating Agent 100%
• Asthma 66%
• Chronic Obstructive Lung Disease 66%
• Base 33%
• Degenerative Disease 33%
• Clinical Trial 33%
• Prescription Drug 33%
• Observational Study 33%
• Agonist-Antagonist 33%
• Bronchiectasis 33%
• Chronic Lung Disease 33%
• Comorbidity 33%
• Diseases 33%

Neuroscience

• Agonist 100%
• Parkinson's Disease 100%
• Sympathomimetic Drug 100%
• Cohort Analysis 100%
• Chronic Obstructive Pulmonary Disease 28%
• Neurodegenerative Disorder 14%
• Diagnosis of Parkinson's Disease 14%
• Comorbidity 14%